Society News2021-08-27T10:57:04+00:00
13May, 2025

OTS Member Highlight – Holly Kordasiewicz, PhD

May 13th, 2025|Categories: Perspectives on Current Science|

Holly Kordasiewicz was a curious, chatty child with a penchant for asking questions. At dinner, conversations were often about the fascinating things her mom, a registered nurse, learned at work, sparking Kordasiewicz's interest in medicine and biology. As her grandparents aged, and she witnessed neurodegenerative diseases gradually and relentlessly chip away at those she loved, her desire to study ...

15April, 2025

OTS Member Highlight – Dr. Annemieke Aartsma-Rus

April 15th, 2025|Categories: Perspectives on Current Science|

Growing up the oldest of four children in Leiden, Netherlands, Dr. Annemieke Aartsma-Rus became fascinated with medical research and genetics as a teenager. While her father's work as a physician made her realize she didn't want to be a doctor, it did teach her that there were numerous diseases with no treatments. In high school, Aartsma-Rus was introduced to ...

19March, 2025

Targeting the Kidney: The Promise of RNA-Based Therapeutics

March 19th, 2025|Categories: Perspectives on Current Science|

When Yessenia Gutierrez was just nine years old, her kidneys failed; at 10 years old, she received her first kidney transplant. Gutierrez was born with polycystic kidney disease (PKD), a genetic condition that makes fluid-filled cysts grow on the kidney and can lead to kidney failure. Growing up, Gutierrez had to stop attending school due to her frequent doctor ...

25February, 2025

2024 FDA Approvals: A Wave of Innovation in Treating Serious Diseases

February 25th, 2025|Categories: Perspectives on Current Science|

In 2024, the Food and Drug Administration Center for Drug Evaluation (CDER) approved 50 new small molecules, biologics, and oligonucleotide therapies (1). The approvals — the second largest in 30 years — include an oligonucleotide therapy for blood cancer, an antisense oligonucleotide shown to significantly drop triglyceride levels, and an mRNA vaccine targeting the respiratory syncytial virus.   IMETELSTAT: ...

12February, 2025

Transporting Therapeutics: A Novel Approach to Deliver ASOs to the Brain

February 12th, 2025|Categories: Perspectives on Current Science|

Antisense oligonucleotide (ASO) therapies, which bind to RNA and modify protein expression, are promising drugs for treating neurological conditions. However, their inability to cross the blood-brain barrier (BBB) sometimes makes injection directly into the cerebral spinal fluid (via intrathecal injection) necessary, which is not without its risks or drawbacks (1). However, a recent study by Denali Therapeutics, as well ...

5February, 2025

Oligonucleotide Treatment Advances Offer Relief for Patients with Familial Chylomicronemia Syndrome

February 5th, 2025|Categories: Perspectives on Current Science|

At just three weeks old, Darlene was sent to the emergency room after her mom had brought her to a pediatrician. The baby wouldn't stop crying and wasn't eating. Concerningly, her triglyceride levels were in the 20,000's, far over the normal 150 level. Darlene was referred to a lipid specialist at John Hopkins University Hospital and, after being genetically ...

Go to Top